Elevated serum bone sialoprotein and osteopontin in colon, breast, prostate, and lung cancer.

PURPOSE Histological studies have shown that the two sialoproteins, bone sialoprotein (BSP) and osteopontin (OPN), are induced in multiple types of cancer. We have recently found that these proteins are bound in serum to complement factor H and that the complex must be disrupted to generate free protein to measure their total levels. We hypothesized that measuring total BSP and OPN levels would provide informative markers for the detection of cancer. EXPERIMENTAL DESIGN As a proof of concept study, serum from patients with diagnosed breast, colon, lung, or prostate cancer (n = 20 for each type) as well as normal serum (n = 77) were analyzed using competitive ELISAs developed for BSP and OPN. Sensitivity, specificity, as well as positive and negative predictive values were determined for each sialoprotein and cancer type. The relationship between sensitivity and specificity was profiled by receiver operating characteristic curves. RESULTS AND CONCLUSIONS Determined values for serum BSP in ng/ml were 285 +/- 19 for prostate, 373 +/- 19 for colon, 318 +/- 18 for breast, 155 +/- 11 for lung cancer sera, and 154 +/- 13 for normal sera. Values of OPN in ng/ml were 653 +/- 39 for prostate, 449 +/- 22 for colon, 814 +/- 53 for breast, 724 +/- 33 for lung, and 439 +/- 30 for normal sera. The assays provide a high degree of sensitivity and specificity that enables the detection of colon, breast, prostate, and lung cancer.

[1]  V. Castronovo,et al.  Expression of bone sialoprotein, a bone matrix protein, in human breast cancer. , 1994, Cancer research.

[2]  E. Manseau,et al.  Osteopontin expression and distribution in human carcinomas. , 1994, The American journal of pathology.

[3]  B. Berse,et al.  Specific reduction in osteopontin synthesis by antisense RNA inhibits the tumorigenicity of transformed Rat1 fibroblasts. , 1994, Oncogene.

[4]  H. Vloedgraven,et al.  Bone sialoprotein peptides are potent inhibitors of breast cancer cell adhesion to bone. , 1996, Cancer research.

[5]  J. F. Harris,et al.  Osteopontin expression in lung cancer. , 1996, Lung cancer.

[6]  F. O'Malley,et al.  Quantification of osteopontin in human plasma with an ELISA: basal levels in pre- and postmenopausal women. , 1996, Clinical biochemistry.

[7]  V. Castronovo,et al.  Bone sialoprotein expression in primary human breast cancer is associated with bone metastases development , 1996, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[8]  S. Ménard,et al.  Expression of bone sialoprotein in primary human breast cancer is associated with poor survival , 1996, International journal of cancer.

[9]  M. Seibel,et al.  Serum immunoreactive bone sialoprotein as a new marker of bone turnover in metabolic and malignant bone disease. , 1996, The Journal of clinical endocrinology and metabolism.

[10]  T. Martin,et al.  Calcitonin receptors, bone sialoprotein and osteopontin are expressed in primary breast cancers , 1997, International journal of cancer.

[11]  F. O'Malley,et al.  Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[12]  V. Castronovo,et al.  Expression of bone matrix proteins in human breast cancer: potential roles in microcalcification formation and in the genesis of bone metastases. , 1997, Bulletin du cancer.

[13]  F. O'Malley,et al.  Osteopontin and p53 expression are associated with tumor progression in a case of synchronous, bilateral, invasive mammary carcinomas. , 1997, Archives of pathology & laboratory medicine.

[14]  J. F. Harris,et al.  Osteopontin expression in a group of lymph node negative breast cancer patients , 1998, International journal of cancer.

[15]  V. Castronovo,et al.  Prognostic value of bone sialoprotein expression in clinically localized human prostate cancer. , 1998, Journal of the National Cancer Institute.

[16]  H. Liapis,et al.  Osteopontin expression in ovarian carcinomas and tumors of low malignant potential (LMP). , 1998, Human pathology.

[17]  S. Hirota,et al.  Possible relation of osteopontin to development of psammoma bodies in human papillary thyroid cancer. , 1998, Archives of pathology & laboratory medicine.

[18]  V. Castronovo,et al.  Ectopic expression of bone sialoprotein in human thyroid cancer. , 1998, Thyroid : official journal of the American Thyroid Association.

[19]  H. Yokozaki,et al.  Co‐expression of osteopontin and CD44v9 in gastric cancer , 1998, International journal of cancer.

[20]  L. Matrisian,et al.  Distinct roles of osteopontin in host defense activity and tumor survival during squamous cell carcinoma progression in vivo. , 1998, Cancer research.

[21]  C. Gilles,et al.  The LCC15-MB human breast cancer cell line expresses osteopontin and exhibits an invasive and metastatic phenotype. , 1998, Experimental cell research.

[22]  U. Studer,et al.  Osteopontin: possible role in prostate cancer progression. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  G. Bastert,et al.  Serum bone sialoprotein in patients with primary breast cancer is a prognostic marker for subsequent bone metastasis. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[24]  M. C. Ling,et al.  Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells , 1999, Oncogene.

[25]  L. Chung,et al.  Osteomimetic properties of prostate cancer cells: A hypothesis supporting the predilection of prostate cancer metastasis and growth in the bone environment , 1999, The Prostate.

[26]  C. Logothetis,et al.  Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. , 2000, Cell calcium.

[27]  V. Castronovo,et al.  Increased Expression of Bone Sialoprotein in Bone Metastases Compared with Visceral Metastases in Human Breast and Prostate Cancers , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[28]  M. Young,et al.  Factor H Binding to Bone Sialoprotein and Osteopontin Enables Tumor Cell Evasion of Complement-mediated Attack* , 2000, The Journal of Biological Chemistry.

[29]  M. Seibel,et al.  Serum bone sialoprotein as a marker of tumour burden and neoplastic bone involvement and as a prognostic factor in multiple myeloma , 2001, British Journal of Cancer.

[30]  D. Torchia,et al.  Flexible structures of SIBLING proteins, bone sialoprotein, and osteopontin. , 2001, Biochemical and biophysical research communications.